Can a powerful cholesterol drug make heart plaques safer?

NCT ID NCT06791031

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a PCSK9 inhibitor (a strong cholesterol-lowering drug) to standard statin therapy can stabilize fatty plaques in the arteries of people who recently had a heart attack. About 212 participants will receive either the drug combination or standard care for 6 months. Doctors will use special imaging to measure changes in plaque thickness and composition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) plus moderate-intensity statin
What this could lead to: If successful, this could show that early use of PCSK9 inhibitors helps stabilize dangerous plaques in heart arteries, potentially reducing future heart attack risk.
What could go wrong: This is a small, early-stage trial (212 people) with no placebo control, so results may not be definitive. The study only looks at plaque changes on imaging, not actual heart attacks, so real-world benefit remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.